- Home
- DT vs INSM Comparison
DT vs INSM Comparison
Compare DT & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DT
- INSM
- Stock Information
- Founded
- DT 2005
- INSM 1988
- Country
- DT United States
- INSM United States
- Employees
- DT N/A
- INSM N/A
- Industry
- DT Computer Software: Prepackaged Software
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- DT Technology
- INSM Health Care
- Exchange
- DT Nasdaq
- INSM Nasdaq
- Market Cap
- DT 13.2B
- INSM 12.5B
- IPO Year
- DT 2019
- INSM 2000
- Fundamental
- Price
- DT $52.49
- INSM $73.81
- Analyst Decision
- DT Buy
- INSM Strong Buy
- Analyst Count
- DT 25
- INSM 16
- Target Price
- DT $60.50
- INSM $83.64
- AVG Volume (30 Days)
- DT 3.3M
- INSM 1.6M
- Earning Date
- DT 11-07-2024
- INSM 10-31-2024
- Dividend Yield
- DT N/A
- INSM N/A
- EPS Growth
- DT N/A
- INSM N/A
- EPS
- DT 0.54
- INSM N/A
- Revenue
- DT $1,563,293,000.00
- INSM $342,958,000.00
- Revenue This Year
- DT $20.03
- INSM $18.96
- Revenue Next Year
- DT $15.61
- INSM $41.96
- P/E Ratio
- DT $97.23
- INSM N/A
- Revenue Growth
- DT 20.58
- INSM 22.13
- 52 Week Low
- DT $39.42
- INSM $21.92
- 52 Week High
- DT $61.41
- INSM $80.53
- Technical
- Relative Strength Index (RSI)
- DT 45.86
- INSM 55.36
- Support Level
- DT $50.09
- INSM $64.86
- Resistance Level
- DT $54.42
- INSM $74.32
- Average True Range (ATR)
- DT 1.65
- INSM 3.09
- MACD
- DT -0.34
- INSM 0.39
- Stochastic Oscillator
- DT 32.88
- INSM 94.61
About DT Dynatrace Inc.
Dynatrace is a cloud-native company that focuses on analyzing machine data. Its product portfolio, delivered as software as a service, allows a client to monitor and analyze its entire IT infrastructure. Dynatrace's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to use it for a variety of applications throughout their businesses.
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.